Scientific publications

Clinical and Economic Evaluation of the Impact of Rapid Microbiological Diagnostic Testing

Jun 19, 2012 | Magazine: The Journal of Infection

A. Galar (a), J. Leiva (a), M. Espinosa (b), F. Guillén-Grima (c), S. Hernáez (a), J.R. Yuste (b)
(a) Department of Clinical Microbiology, Clinica Universidad de Navarra, Pamplona, Spain
(b) Infectious Diseases Division, Clinica Universidad de Navarra, Pamplona, Spain
(c) Preventive Medicine Division, Clinica Universidad de Navarra, Pamplona, Spain

The clinical value of information provided by the Microbiology Laboratory may be reduced by the time it takes to generate results for healthcare providers. The aim of this study was to measure the clinical and economic impact associated with rapid reporting of microbiological results.

574 hospitalized patients with a bacterial clinical infection confirmed by culture were evaluated. 284 hospitalized patients were included in the historical control group (results available the day following the analysis) and 290 in the intervention group (results available the same day of the analysis). The Vitek® 2 system (bioMérieux) was used for identification and antimicrobial susceptibility testing in both groups.

Faster reporting of microbiological results enabled the clinician to optimize the antibiotic treatment sooner (P<0.001). This reduction in turnaround time (17.6h) was associated with improved clinical outcome, a significant reduction in the length of hospitalization and the number of microbiological and biochemical tests performed. Intubation requirements were significantly lower in the intervention group. Mortality rates did not differ significantly between the two groups.

Costs incurred for patients in the intervention group were significantly lower than those in the control group, including costs for Microbiology Laboratory testing, antibiotic costs, length of hospitalization and other patient care costs.

Rapid microbiological information was associated with quality improvement seen in earlier changes in antibiotic use, an improved clinical outcome and financial benefits.

CITATION   2012 Jun 19